NEW YORK, Oct. 20, 2016 -- Progyny, a leading digital healthcare company, today announced it will rebrand its direct-to-consumer products under the parent company. The rebrand will also include the launch of a new website and new features available for patients looking to learn more about their fertility options and journey.
Progyny’s direct-to-consumer products, EggBanxx will now be Progyny Egg Freezing, and IVFAdvantage, will now be Progyny IVF. Progyny Egg Freezing will continue to provide information and a plan for women interested in preserving their fertility through egg freezing. Progyny IVF will continue to provide a no-restriction in vitro fertilization (IVF) plan and be accessible to any individual or couple who might be struggling to conceive. Both products will provide individuals with exclusive pricing, financing and support from the company’s patient care advocates and best in care treatment from its national network of elite fertility doctors and clinics.
The new website will feature Progyny’s clinical and proprietary software technology, EEVA® (early embryo viability assessment). EEVA is the first and only FDA-cleared, non-invasive embryo assessment tool for IVF patients. Over the next several quarters, Progyny is planning to introduce additional software tools to help improve outcomes and provide more choice for patients.
“Our dedication and investment in proprietary, clinical technology is part of our mission to help anyone who wants to have a baby, have a healthy one. We want to give our patients and doctors the confidence of knowing they’ve made the right choice,” said Gina Bartasi, CEO of Progyny.
The launch of the new website aims to make it easier for consumers and employer members with Progyny fertility benefits to navigate through their options, select a doctor, and better understand their best course of treatment. The website will allow users to request appointment times with top experts across the country. In addition, similar to the Progyny App, the website will provide users with success rates, patient ratings, pricing, the ability to speak with a patient care advocate for support, and offer education through curated content, videos, and FAQs.
“By bringing all of our products under one brand, we aim for Progyny to be a household name and the go to source for all fertility solutions. This rebrand is just the first step,” added Bartasi.
“We are excited for this new phase and look to roll out new features including the ability for members to easily access their benefit claims information, a fertility calculator and IVF predictor tool,” said George Nassef, EVP of Operations and CTO.
The new features will continue to be released by the end of this year and into 2017.
For more information and to visit the new website please visit, www.progyny.com.
About Progyny:
Progyny is a leading digital healthcare company combining data, science and technology to provide the first end-to-end, proactive fertility solution for both large, self-insured employers and today’s informed consumer. Progyny’s SMART™ Cycle plan design comprises best-in-class research and clinical solutions, including its proprietary EEVA® technology, to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. Progyny is privately held and is headquartered in New York, NY, with operations in San Francisco, CA. Please visit www.progyny.com.
Media Contact: Selena Yang [email protected] Phone: 646-768-9719


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 



